Friday, December 9, 2016

BRIEF-Eli lilly says Solanezumab did not meet primary endpoint in expedition3 clinical trial

* Will not pursue regulatory submissions for Solanezumab for

treatment of mild dementia due to AD

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)